Alzheimer's disease (AD) remains a significant global health challenge, characterized by its progressive neurodegeneration and cognitive decline. The urgent need for early diagnosis and effective treatment necessitates the identification of reliable biomarkers that can illuminate the underlying pathophysiology of AD. This review provides a comprehensive overview of the latest advancements in biomarker research, focusing on their applications in diagnosis, prognosis, and therapeutic development. We delve into the multifaceted landscape of AD biomarkers, encompassing molecular, imaging, and fluid-based markers. The integration of these biomarkers, including amyloid-β and tau proteins, neuroimaging modalities, cerebrospinal fluid analysis, and genetic risk factors, offers a more nuanced understanding of AD's complex etiology. By leveraging the power of precision medicine, biomarker-driven approaches can enable personalized treatment strategies and enhance diagnostic accuracy. Moreover, this review highlights the potential of biomarker research to accelerate drug discovery and development. By identifying novel therapeutic targets and monitoring disease progression, biomarkers can facilitate the evaluation of experimental treatments and ultimately improve patient outcomes. In conclusion, this review underscores the critical role of biomarkers in advancing our comprehension of AD and driving the development of effective interventions. By providing a comprehensive overview of the current state-of-the-art, this work aims to inspire future research and contribute to the goal of conquering AD.
ZeiselJBennettKFlemingR. World Alzheimer Report 2020. Design, dignity, dementia: Dementia-related design and the built environment. London: Alzheimer’s Disease International, 2020.
9.
MorrisGPClarkIAVisselB. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun2014; 2: 135.
10.
HillenH. The beta amyloid dysfunction (BAD) hypothesis for Alzheimer’s disease. Front Neurosci2019; 13: 1154.
11.
ParoniGBiscegliaPSeripaD. Understanding the amyloid hypothesis in Alzheimer's disease. J Alzheimers Dis2019; 68: 493–510.
12.
KarranEMerckenMStrooperB. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov2011; 10: 698–712.
13.
SelkoeDJHardyJ. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med2016; 8: 595–608.
14.
BertramLTanziRE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci2008; 9: 768–778.
15.
BenilovaIKarranEDe StrooperB. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci2012; 15: 349–357.
16.
WalshDMKlyubinIFadeevaJV, et al.Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature2002; 416: 535–539.
17.
ThalDRRübUOrantesM, et al.Phases of Aβ deposition in the human brain and its relevance for the development of AD. Neurology2002; 58: 1791–1800.
18.
KarranEDe StrooperB. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov2022; 21: 306–318.
19.
IttnerLMGötzJ. Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci2011; 12: 65–72.
20.
HenekaMTCarsonMJEl KhouryJ, et al.Neuroinflammation in Alzheimer's disease. Lancet Neurol2015; 14: 388–405.
21.
BatemanRJHoltzmanDM. Apolipoprotein E mediates amyloid-β clearance from the central nervous system in an isoform-dependent manner. Nat Med2000; 6: 136–138.
22.
KlunkWEEnglerHNordbergA, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol2004; 55: 306–319.
23.
BlennowKZetterbergH. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
24.
WeinerMWVeitchDPAisenPS, et al.Recent publications from the Alzheimer's disease neuroimaging initiative: reviewing progress toward improved AD clinical trials. Alzheimers Dement2017; 13: e1–e85.
25.
JohnsonKAMinoshimaSBohnenNI, et al.Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's Association. Alzheimers Dement2013; 9: e1–e16.
26.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 280–292.
27.
SevignyJChiaoPBussièreT, et al.The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature2016; 537: 50–56.
28.
HampelHO'BryantSEMolinuevoJL, et al.Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol2018; 14: 639–652.
29.
AvilaJHernándezF. Tauopathies. Cell Mol Life Sci2021; 78: 2253–2254.
30.
MandelkowEMMandelkowE. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med2012; 2: a006247.
31.
IqbalKLiuFGongCX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol2016; 12: 15–27.
32.
GoedertMSpillantiniMG. A century of Alzheimer's disease. Science2019; 365: 77–78.
33.
BraakHBraakE. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
34.
WangYMandelkowE. Tau in physiology and pathology. Nat Rev Neurosci2016; 17: 5–21.
35.
BartenDMFanaraPAndorferC, et al.Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci2012; 32: 7137–7145.
36.
HuttonMLendonCLRizzuP, et al.Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature1998; 393: 702–705.
37.
UmedaTMaekawaSKimuraT, et al.Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol2014; 127: 685–698.
38.
VillemagneVLDoreVBourgeatP, et al.Aβ- and tau-positive amyloid PET imaging in Alzheimer's disease. Alzheimers Dement2017; 13: 1152–1161.
39.
JanelidzeSMattssonNPalmqvistS, et al.Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology, and longitudinal progression to Alzheimer's dementia. Nat Med2020; 26: 379–386.
40.
SpillantiniMGGoedertM. Tau pathology and neurodegeneration. Lancet Neurol2013; 12: 609–622.
41.
GötzJIttnerLM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci2008; 9: 532–544.
42.
Lasagna-ReevesCACastillo-CarranzaDLGuerrero-MuñozMJ, et al.Preparation and characterization of neurotoxic tau oligomers. Biochemistry2010; 49: 10039–10041.
ChiotisKSaint-AubertLSavitchevaI, et al.Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging2016; 43: 1686–1699.
45.
SchöllMLockhartSNSchonhautDR, et al.PET Imaging of tau deposition in the aging human brain. Neuron2016; 89: 971–982.
46.
MattssonNAndreassonUPerssonS, et al.The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement2011; 7: 386–395.
47.
ToledoJBBjerkeMDaX, et al.Nonlinear association between cerebrospinal fluid and Florbetapir F-18 β-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol2015; 72: 571–581.
48.
JohnsonKASchultzABetenskyRA, et al.Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol2016; 79: 110–119.
49.
PontecorvoMJDevousMDSrKennedyI, et al.A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment, and Alzheimer's disease dementia. Brain2019; 142: 1723–1735.
50.
ChoHChoiJYHwangMS, et al.In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol2016; 80: 247–258.
51.
ArbabshiraniMRPlisSSuiJ, et al.Single subject prediction of brain disorders in neuroimaging: promises and pitfalls. Neuroimage2017; 145: 137–165.
52.
LamBMasellisMFreedmanM, et al.Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther2013; 5: 1.
53.
FrisoniGBFoxNCJackCRJr, et al.The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol2010; 6: 67–77.
54.
ApostolovaLGThompsonPM. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia2007; 45: 1591–1602.
55.
BucknerRLSnyderAZShannonBJ, et al.Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci2005; 25: 7709–7717.
56.
DouaudGMenkeRAGassA, et al.Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J Neurosci2013; 33: 2147–2155.
57.
RamananVKRisacherSLNhoK, et al.GWAS Of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain2014; 137: 3076–3084.
58.
BullichSSeibylJCatafauAM, et al.Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin2017; 15: 325–332.
59.
SchottJMBartlettJWFoxNC, et al.Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1–42. Ann Neurol2010; 68: 825–834.
60.
OssenkoppeleRRabinoviciGDSmithR, et al.Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA2018; 320: 1151–1162.
61.
JackCRJrKnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol2010; 9: 119–128.
62.
DuATSchuffNAmendD, et al.Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry2001; 71: 441–447.
63.
BarnesJBartlettJWvan de PolLA, et al.A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging2009; 30: 1711–1723.
64.
SperlingRAJohnsonKADoraiswamyPM, et al.Amyloid deposition detected with florbetapir F 18 ((18) F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging2013; 34: 822–831.
65.
XiaCFArteagaJChenG, et al.[18f] T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement2013; 9: 666–676.
66.
PievaniMde HaanWWuT, et al.Functional network disruption in the degenerative dementias. Lancet Neurol2011; 10: 829–843.
67.
DesikanRSSegonneFFischlB, et al.An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage2006; 31: 968–980.
68.
BrierMRThomasJBFaganAM, et al.Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiol Aging2014; 35: 757–768.
69.
JackCRJrPetersenRCXuYC, et al.Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology1998; 52: 1397–1403.
70.
CeloneKACalhounVDDickersonBC, et al.Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci2006; 26: 10222–10231.
71.
DickersonBCWolkDA. MRI Cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology2011; 78: 84–90.
72.
ShelineYIRaichleMESnyderAZ, et al.Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry2010; 67: 584–587.
73.
FoxNCCousensSScahillR, et al.Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease. Arch Neurol2000; 57: 339–344.
74.
LeowADKlunderADJackCRJr, et al.Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage2006; 31: 627–640.
75.
WangJZuoXDaiZ, et al.Disrupted functional brain connectome in individuals at risk for Alzheimer's disease. Biol Psychiatry2013; 73: 472–481.
76.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
77.
ApostolovaLGGreenAEBabakchanianS, et al.Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer disease. Alzheimer Dis Assoc Disord2012; 26: 17–27.
78.
Iturria-MedinaYCarbonellFMSoteroRC, et al.Multifactorial causal model of brain (dis)organization and therapeutic intervention: application to Alzheimer's disease. Neuroimage2017; 152: 60–77.
79.
BarthélemyNRTothBManserPT, et al.Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer’s disease brain pathology: not all tau phospho-sites are hyperphosphorylated. J Alzheimers Dis2022; 85: 415–429.
80.
BlennowKHampelHWeinerM, et al.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol2010; 6: 131–144.
81.
LlorensFSchmitzMVargesD, et al.Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol2016; 263: 2271–2277.
82.
HanssonOZetterbergHBuchhaveP, et al.Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol2006; 5: 228–234.
83.
MattssonNZetterbergHHanssonO, et al.CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009; 302: 385–393.
84.
JanelidzeSStomrudEPalmqvistS, et al.Cerebrospinal fluid biomarkers of neurodegeneration for diagnosis and prediction of clinical progression in Alzheimer's disease. J Intern Med2020; 288: 30–40.
85.
BrierMRGordonBFriedrichsenK, et al.Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med2016; 8: 338ra66.
86.
ListaSHampelH. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. Expert Rev Neurother2017; 17: 47–57.
ShawLMVandersticheleHKnapik-CzajkaM, et al.Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol2009; 65: 403–413.
89.
TeunissenCEPetzoldABennettJL, et al.A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology2009; 73: 1914–1922.
90.
HanssonOEdelmayerRMBoxerAL, et al.The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement2022; 18: 2669–2686.
91.
KarikariTKPascoalTAAshtonNJ, et al.Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol2020; 19: 422–433.
92.
MielkeMMKueiderAM. Plasma tau: a window into the preclinical stages of Alzheimer disease?JAMA Neurol2019; 76: 784–786.
93.
BridelCvan WieringenWNZetterbergH, et al.Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol2019; 76: 1035–1048.
94.
TrushinaEMielkeMM. Recent advances in the application of metabolomics to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis2014; 1842: 1232–1239.
95.
KumarSReddyPH. MicroRNA-455-3p as a potential biomarker for Alzheimer's disease: an update. Front Aging Neurosci2016; 8: 290.
96.
GoetzlEJKapogiannisDSchwartzJB, et al.Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB J2016; 30: 4141–4148.
97.
PreischeOSchultzSAApelA, et al.Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med2019; 25: 277–283.
98.
Karch CM an d GoateAM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry2015; 77: 43–51.
99.
MielkeMMCummingsJL. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging2015; 36: S10–S17.
100.
CorderEHSaundersAMStrittmatterWJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993; 261: 921–923.
101.
MorrisJCRoeCMXiongC, et al.APOE Predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol2010; 67: 122–131.
102.
LiuCCLiuCCKanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
103.
LambertJCIbrahim-VerbaasCAHaroldD, et al.Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet2013; 45: 1452–1458.
104.
NeuSCPaJKukullW, et al.Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol2017; 74: 1178–1189.
JackCRJrPetersenRCXuY, et al.Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology1998; 51: 993–999.
107.
Escott-PriceVSimsRBannisterC, et al.Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain2015; 138: 3673–3684.
108.
GreenRCRobertsJSCupplesLA, et al.Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med2009; 361: 245–254.
109.
FarrerLACupplesLAHainesJL, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA1997; 278: 1349–1356.
110.
RaberJHuangYAshfordJW. Apoe genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging2004; 25: 641–650.
111.
LambertJCHeathSEvenG, et al.Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet2009; 41: 1094–1099.
112.
HaroldDAbrahamRHollingworthP, et al.Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet2009; 41: 1088–1093.
113.
GuerreiroRHardyJ. Genetics of Alzheimer's disease. Neurotherapeutics2014; 11: 732–737.
114.
HolmesCCunninghamCZotovaE, et al.Systemic inflammation and disease progression in Alzheimer disease. Neurology2009; 73: 768–774.
115.
SwardfagerWLanctôtKRothenburgL, et al.A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry2010; 68: 930–941.
116.
GalimbertiDSchoonenboomNScheltensP, et al.Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol2006; 63: 538–543.
117.
GlassCKSaijoKWinnerB, et al.Mechanisms underlying inflammation in neurodegeneration. Cell2010; 140: 918–934.
118.
SchmidtRSchmidtHCurbJD, et al.Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol2002; 52: 168–174.
119.
UttaraBSinghAVZamboniP, et al.Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol2009; 7: 65–74.
120.
Rubio-PerezJMMorillas-RuizJM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorld J2012; 2012.
121.
ColonnaMButovskyO. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol2017; 35: 441–468.
122.
HenekaMTO'BanionMK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol2007; 184: 69–91.
123.
McGeerPLMcGeerEG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging2007; 28: 639–647.
124.
SchafferCSaradNDeCrumpeA, et al.Biomarkers in the diagnosis and prognosis of Alzheimer’s disease. J Lab Autom2015; 20: 589–600.
125.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
126.
JackCRJrBennettDABlennowK, et al.A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology2016; 87: 539–547.
127.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
128.
BjerkeMEngelborghsSCavedoE, et al.Staging β-amyloid pathology with standardized voxelwise PiB PET analyses. Alzheimers Dement2018; 14: 1069–1079.
129.
PanzaFLozuponeMSolfrizziV, et al.BDNF Rs6265 methylation and genotype interact on risk of Alzheimer's disease. Aging Clin Exp Res2018; 30: 727–735.
130.
JansenWJOssenkoppeleRKnolDL, et al.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA2015; 313: 1924–1938.
131.
O'BryantSEGuptaVHenriksenK, et al.Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement2015; 11: 549–560.
NovakPKontsekovaEZilkaN, et al.Ten years of tau-targeted immunotherapy: the path walked and the roads ahead. Front Neurosci2018; 12: 798.
135.
JichaGANelsonPT. Management of frontotemporal dementia spectrum disorders: potential benefits and challenges of multidisciplinary care. Front Neurol2018; 9: 931.
136.
ZhangWTarutaniANewellKL, et al.Novel tau filament fold in corticobasal degeneration. Nature2020; 580: 283–287.
137.
CoughlinDXieSXLiangM, et al.Cognitive and pathological influences of tau pathology in Lewy body disorders. Ann Neurol2021; 89: 892–906.
138.
HampelHFrankRBroichK, et al.Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov2010; 9: 560–574.
139.
MuellerCPereraGHayesRD, et al.Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. Age Ageing2017; 46: 439–444.
140.
MorminoECPappKVRentzDM, et al.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement2020; 16: 1187–1199.
141.
CummingsJFeldmanHHScheltensP, et al.Trial designs used to study the effect of disease-modifying therapies on Alzheimer's disease progression: a review. Alzheimers Dement2014; 10: 684–695.
142.
La MorgiaCRoss-CisnerosFNSadunAA, et al.Retinal ganglion cells and circadian rhythms in Alzheimer's disease, Parkinson's disease, and beyond. Front Neurol2018; 9: 162.
Serrano-PozoAQianJMonsellSE, et al.Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol2013; 75: 597–601.
145.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
146.
NortonSMatthewsFEBarnesDE, et al.Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol2014; 13: 788–794.
147.
HenjumKAlmdahlISÅrskogV, et al.Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther2016; 8: 17.
148.
RajAKuceyeskiAWeinerM. A network diffusion model of disease progression in dementia. Neuron2012; 73: 1204–1215.
